Case Study
Jazz Pharmaceuticals takes an Integrated Approach to RBQM with the elluminate Clinical Data Cloud
PROJECT BACKGROUND Following the successful implementation of the elluminate Clinical Data Cloud®, Jazz Pharmaceuticals wanted to launch the next phase of their clinical data strategy by integrating a comprehensive Risk-Based Quality Management (RBQM) solution.
COMPANY PROFILE
Jazz had implemented elluminate to centralize all of the company’s clinical trial data - from many sources and of varying types - which provided a single source of truth and enabled real-time access to the data across stakeholders. With the elluminate Mapper, Data Central, and Clinical Analytics products, they had the ability to transform, review, and analyze data from a single platform.
■
Mapper
■
Clinical Analytics
■
Data Central
■
Risk-based Quality Management (RBQM)
■
Global, Mid-sized BioPharma
■
~ $4 Billion+ in Revenue
■
~ 2,800+ Employees
PRODUCTS
By migrating data into elluminate, the company had already unlocked numerous new efficiencies, elluminate RBQM would allow Jazz Pharmaceuticals to take the next step in the evolution of their clinical data infrastructure.
THE CHALLENGE Jazz began by setting some core objectives and wanted to pilot and assess an RBQM and risk-assessment and categorization tool (RACT) by the end of 2022. It was important to the team that there be a strong connection between the RACT and RBQM solution. The solutions needed to integrate with existing workflows but be flexible enough to accommodate future process changes.